Conatus Pharmaceuticals Inc (NASDAQ:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results …
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced that a late-breaking abstract detailing results from the company’s multicenter Phase 2 Portal Hypertension clinical trial in patients with …
Analysts are weighing in on two biotechnology companies Keryx Pharmaceutical (NASDAQ:KERX) and Conatus Pharmaceuticals Inc (NASDAQ:CNAT), with mixed ratings. Keryx Pharmaceutical BTIG analyst Hartaj Singh came out with a …
Roth Capital’s healthcare analyst Elemer Piros weighed in today with his views on Conatus Pharmaceuticals Inc (NASDAQ:CNAT), after the company announced positive data on the early …
Keryx Biopharmaceuticals (NASDAQ:KERX) rose more than 12% in pre-market trading up to $4.40 after this morning’s announcement that the company received approval in Europe …
In a research report released Wednesday, Brean Capital analyst Difei Yang reiterated a Buy rating on Conatus Pharmaceuticals Inc (NASDAQ:CNAT) with a $13 price …
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) shares jumped over 9% in pre market trading to $12.98 after its New Drug Application for MM-398 was accepted for …
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced pre-treatment biomarker and histology data from the first 16 patients enrolled in the company’s Phase 2b clinical trial of …
Conatus Pharmaceuticals Inc (NASDAQ:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced the appointment of …
